Price & volume screen · refreshed after the Nov 12, 2026 close

New highs

Stocks that closed at their highest level of the trailing year. A close above every other close in the trailing window. Stocks making new highs have no overhead supply from buyers waiting to break even, which is why many momentum approaches start here.

CriteriaClose ≥ every close in the trailing windowPrice ≥ $2Market cap ≥ $300M70 stocks
#CompanyPriceToday1M6MMkt cap
51GIWGigCapital8Financials$10.210.00%+0.1%+1.8%$372.4M
52TACHTitan AcquisitionFinancials$10.59+0.09%+0.5%+2.2%$365.4M
53SOULSoulpower AcquisitionFinancials$10.55+0.05%+0.6%+2.1%$358.2M
54AFRIForafric GlobalUnclassified$13.13+0.84%+9.1%+28.7%$354.0M
55TMCITreace Medical ConceptsHealthcare$5.34+5.53%+32.2%+92.8%$350.1M
56HCMAHCM III AcquisitionFinancials$10.340.00%+0.4%+1.9%$348.8M
57CBNAChain Bridge BancorpFinancials$52.48+0.25%+7.5%+42.6%$344.4M
58USDUWisdomTree Bloomberg U.S. Dollar Bullish FundFund$27.45+0.18%+1.0%+5.3%$343.1M
59BLUWBlue Water Acquisition Corp. IIIFinancials$10.44+0.05%+0.4%+1.8%$337.1M
60KINSKingstone CompaniesFinancials$23.23+3.06%+26.0%+56.3%$336.4M
61HLPHongli GroupUnclassified$4.43+1.37%+48.7%+330.1%$331.1M
62DRDBRoman DBDR Acquisition Corp. IIFinancials$10.79+0.09%+0.3%+2.5%$330.9M
63SZZLSizzle Acquisition Corp. IIFinancials$10.540.00%+0.3%+2.1%$329.6M
64KOYNCSLM Digital Asset Acquisition Corp IIIFinancials$10.30+0.05%+0.3%+1.8%$324.9M
65JACSJackson Acquisition Company IIFinancials$10.86+0.09%+0.3%+2.5%$321.3M
66LWACLightWave AcquisitionFinancials$10.42+0.19%+0.6%+2.4%$313.4M
67RACRithm AcquisitionFinancials$10.63+0.28%+0.5%+2.1%$312.6M
68OTGAOTG Acquisition Corp. IFinancials$10.32+0.24%+0.5%+1.9%$304.6M
69HVMCHighview MergerFinancials$10.32+0.19%—+2.1%$303.5M
70GSRFGSR IV AcquisitionFinancials$10.310.00%+0.4%+1.8%$303.2M

Method & sources

Computed after each close from Massive / Polygon prices (split-adjusted), SEC filings, FINRA short-interest settlements and FMP earnings dates. Rows are rebuilt every session; a stock appears only when every criterion is met with current data. Full methodology

Informational screen, not a recommendation.